Head-To-Head Contrast: Blueprint Medicines (NASDAQ:BPMC) versus SAGE Therapeutics (SAGE)

Blueprint Medicines (NASDAQ: BPMC) and SAGE Therapeutics (NASDAQ:SAGE) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Institutional & Insider Ownership

83.5% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 95.3% of SAGE Therapeutics shares are owned by institutional investors. 3.4% of Blueprint Medicines shares are owned by insiders. Comparatively, 6.1% of SAGE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


This table compares Blueprint Medicines and SAGE Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Blueprint Medicines -437.83% -43.11% -34.38%
SAGE Therapeutics N/A -89.46% -78.94%

Volatility and Risk

Blueprint Medicines has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, SAGE Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Blueprint Medicines and SAGE Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines 0 0 10 0 3.00
SAGE Therapeutics 1 1 12 0 2.79

Blueprint Medicines presently has a consensus target price of $83.78, indicating a potential upside of 5.73%. SAGE Therapeutics has a consensus target price of $171.21, indicating a potential downside of 2.64%. Given Blueprint Medicines’ stronger consensus rating and higher probable upside, equities analysts clearly believe Blueprint Medicines is more favorable than SAGE Therapeutics.

Earnings & Valuation

This table compares Blueprint Medicines and SAGE Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Blueprint Medicines $27.77 million 122.36 -$72.49 million ($3.41) -23.24
SAGE Therapeutics N/A N/A -$158.98 million ($6.87) -25.60

Blueprint Medicines has higher revenue and earnings than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.


Blueprint Medicines beats SAGE Therapeutics on 8 of the 13 factors compared between the two stocks.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

About SAGE Therapeutics

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply